CaMKII autophosphorylation in opposing directions of synaptic plasticity

突触可塑性相反方向的 CaMKII 自磷酸化

基本信息

  • 批准号:
    9891100
  • 负责人:
  • 金额:
    $ 33.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

The Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a major mediator of cellular Ca2+- signals. CaMKII is a multifunctional protein kinase that participates in a variety of different signaling events, which intriguingly can have opposing signaling outcomes (such as cell death versus survival, proliferation versus cell cycle arrest, and potentiation versus depression of synaptic strength). However, the mechanisms that differentiate between such opposing signaling outcomes mediated by CaMKII are currently unclear. A long-proposed attractive mechanism is differential CaMKII auto-phosphorylation at T286, which renders the kinase partially “autonomous” (i.e. Ca2+-independent). However, experimental evidence is lacking, and preliminary studies of this proposal led to the alternative hypothesis that differentiation is instead mediated by auto-phosphorylation at T305/306, which prevents Ca2+/CaM binding to the kinase. The specific signaling outcomes studied here are long-term potentiation (LTP) and depression (LTD) of synaptic strength, two opposing forms of Ca2+-dependent synaptic plasticity that are induced by high or low frequency stimulation, respectively, and are thought to underlie learning and memory. Over 22 years of research has firmly linked CaMKII to LTP regulation, while CaMKII requirement in LTD is just emerging (including by the preliminary results of this proposal). Contrary to traditional models, T286 auto-phosphorylation is efficiently induced by both LTP- and LTD-stimuli. By contrast, preliminary results indicate that T305/306 auto- phosphorylation is induced exclusively by LTD- but not LTP-stimuli. Theoretical arguments can be made for the biochemical mechanisms that may underlie such stimulus-dependent differential T305/306 autophosphorylation. However, in contrast to the well-studied T286 auto-phosphorylation, little is currently known about the actual holoenzyme mechanisms governing T305/306 phosphorylation. Another important question is how T305/306 auto-phosphorylation may then lead to the opposing down-stream consequences. Preliminary results indicate that it can cause differential CaMKII substrate selection that should indeed promote LTD and suppress LTP. Thus, this proposal will: (1) determine the holoenzyme mechanism underlying the LTD-specific induction (and LTP-specific suppression) of T305/306 phosphorylation, (2) determine the specific occurance and requirement of T305/306 phosphorylation in LTD, (3) determine the requirement for T305/306 (and T286) phosphorylation in communicating excitatory LTP- or LTD-stimuli to inhibitory synapses, where these stimuli induce plasticity in the opposite direction. The results will provide a new conceptual and mechanistic framework of how a single mediator can be required in signal transduction events with opposing outcomes. A better understanding of the specific mechanism studies here will also have impact on new therapeutic strategies for Angelman Syndrome, where a CaMKII T305/306 hyper-phosphorylation is involved in synaptic and learning dysfunctions.
Ca2+/钙调蛋白(CaM)依赖性蛋白激酶II (CaMKII)是细胞Ca2+-的主要介质

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

K. Ulrich Bayer其他文献

K. Ulrich Bayer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('K. Ulrich Bayer', 18)}}的其他基金

CaMKII in global cerebral ischemia: mechanisms and therapeutic intervention
CaMKII 在全脑缺血中的作用:机制和治疗干预
  • 批准号:
    10531925
  • 财政年份:
    2021
  • 资助金额:
    $ 33.75万
  • 项目类别:
CaMKII in global cerebral ischemia: mechanisms and therapeutic intervention
CaMKII 在全脑缺血中的作用:机制和治疗干预
  • 批准号:
    10328983
  • 财政年份:
    2021
  • 资助金额:
    $ 33.75万
  • 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
  • 批准号:
    10222559
  • 财政年份:
    2020
  • 资助金额:
    $ 33.75万
  • 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
  • 批准号:
    10454912
  • 财政年份:
    2020
  • 资助金额:
    $ 33.75万
  • 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
  • 批准号:
    10671685
  • 财政年份:
    2020
  • 资助金额:
    $ 33.75万
  • 项目类别:
CaMKII nitrosylation in the age-related decline of synaptic plasticity
CaMKII 亚硝基化在与年龄相关的突触可塑性下降中的作用
  • 批准号:
    10444721
  • 财政年份:
    2020
  • 资助金额:
    $ 33.75万
  • 项目类别:
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunction
β淀粉样蛋白诱导的突触功能障碍中的突触后激酶/磷酸酶网络
  • 批准号:
    10450777
  • 财政年份:
    2018
  • 资助金额:
    $ 33.75万
  • 项目类别:
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunction
β淀粉样蛋白诱导的突触功能障碍中的突触后激酶/磷酸酶网络
  • 批准号:
    10207804
  • 财政年份:
    2018
  • 资助金额:
    $ 33.75万
  • 项目类别:
Postsynaptic kinase/phosphatase networks in amyloid beta-induced synaptic dysfunction
β淀粉样蛋白诱导的突触功能障碍中的突触后激酶/磷酸酶网络
  • 批准号:
    9791023
  • 财政年份:
    2018
  • 资助金额:
    $ 33.75万
  • 项目类别:
Restoring synaptic function in Down Syndrome mice
恢复唐氏综合症小鼠的突触功能
  • 批准号:
    9340289
  • 财政年份:
    2016
  • 资助金额:
    $ 33.75万
  • 项目类别:

相似国自然基金

天使症候群(Angelman Syndrome,AS)TrkB信号损伤的机制研究及靶向干预
  • 批准号:
    31371139
  • 批准年份:
    2013
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目

相似海外基金

The Role of Sensory Receptors in Angelman Syndrome
感觉感受器在天使综合症中的作用
  • 批准号:
    10630683
  • 财政年份:
    2023
  • 资助金额:
    $ 33.75万
  • 项目类别:
Small Molecule Therapeutic Discovery for Angelman Syndrome
天使综合症的小分子治疗发现
  • 批准号:
    10636253
  • 财政年份:
    2023
  • 资助金额:
    $ 33.75万
  • 项目类别:
Interaction of Myelin-Axon reveled new pathological mechanism in angelman syndrome
髓鞘-轴突的相互作用揭示了天使综合征的新病理机制
  • 批准号:
    22K07868
  • 财政年份:
    2022
  • 资助金额:
    $ 33.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Determining minimal clinically important differences for neurodevelopmental outcome measures in Angelman syndrome
确定天使综合征神经发育结果测量的最小临床重要差异
  • 批准号:
    10186591
  • 财政年份:
    2021
  • 资助金额:
    $ 33.75万
  • 项目类别:
Determining minimal clinically important differences for neurodevelopmental outcome measures in Angelman syndrome
确定天使综合征神经发育结果测量的最小临床重要差异
  • 批准号:
    10396549
  • 财政年份:
    2021
  • 资助金额:
    $ 33.75万
  • 项目类别:
Contribution of GABA-A receptor subunit deletions to Angelman syndrome pathophysiology
GABA-A 受体亚基缺失对 Angelman 综合征病理生理学的贡献
  • 批准号:
    10391880
  • 财政年份:
    2021
  • 资助金额:
    $ 33.75万
  • 项目类别:
Gene Therapy Rescue of Angelman Syndrome with Reelin
Reelin 基因疗法拯救天使综合症
  • 批准号:
    10317654
  • 财政年份:
    2021
  • 资助金额:
    $ 33.75万
  • 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
  • 批准号:
    10490828
  • 财政年份:
    2019
  • 资助金额:
    $ 33.75万
  • 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
  • 批准号:
    10237150
  • 财政年份:
    2019
  • 资助金额:
    $ 33.75万
  • 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
  • 批准号:
    10011898
  • 财政年份:
    2019
  • 资助金额:
    $ 33.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了